PricewaterhouseCoopers (PwC) Health Research Institute (HRI) recently released its report on the midterm elections, “Healthcare after the 2018 midterm elections: As control shifts, certainty settles in.”
HRI’s report analyzes policy issues that are likely to impact the U.S. health care industry over the next two years and should be included in your business strategy discussions.
Some notable industry impacts explored:
Enjoying this article? You may also enjoy this White Paper:
Top Five Ways Automation Can Boost Financial Success in the Life Sciences IndustriesDownload Free White Paper
HRI also conducted a consumer survey in the weeks before the election, and the report explores Americans’ sentiments toward health policy. For example, 59 percent Americans surveyed by HRI cited health care as a very important issue for them during the election. Health care ranked as the first or second priority for Americans surveyed by HRI across age, race and geographic region.
In an increasingly complex policy and regulatory landscape where the health care industry of the future is being redefined, HRI’s report can help you identify and evaluate opportunities and obstacles that will impact your organization. Read the full report at https://www.pwc.com/us/healthcare2018midterms.
PwC's HRI provides new intelligence, perspectives and analysis on trends affecting all health-related industries. HRI helps executive decision-makers navigate change through primary research and collaborative exchange. Our views are shaped by a network of professionals with executive and day-to-day experience in the health industry.
In October 2018, MasterControl Inc. and PricewaterhouseCoopers (PwC) announced a new partnership designed to deliver industry-leading quality and compliance solutions to companies across the globe. The strategic partnership is designed to provide a seamless collaboration of regulatory expertise and enterprise-level best practices. MasterControl is a leading provider of software solutions that enable regulated companies to deliver life-improving products to more people sooner. These solutions will now become part of the PwC strategic offering.
PwC’s Pharmaceutical and Life Sciences Industry Group is dedicated to delivering effective solutions to the complex strategic, operational and financial challenges facing pharmaceutical, biotechnology and medical devices companies. We provide industry-focused assurance, tax and advisory services to build public trust and enhance value for our clients and their stakeholders. More than 250,000 people in 158 countries across the PwC global network of firms share their thinking, experience, and solutions to develop fresh perspectives and practical advice. Visit us at www.pwc.com/us/pharma.